Lemtrada market set for rapid growth as MS cases rise

The Business Research Company says the global Lemtrada market is entering a period of rapid growth, driven by rising multiple sclerosis cases, personalized medicine, and higher healthcare spending. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest in the years ahead.

Why it matters: - The Lemtrada market is tied to the growing need for high-efficacy multiple sclerosis treatments. - Rising MS prevalence, broader use of personalized medicine, and higher healthcare spending are expanding access to advanced autoimmune therapies. - The market outlook suggests stronger demand for biologic drugs, infusion monitoring tools, and long-term disease-modifying care.

What happened: - The Business Research Company published its Lemtrada Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 5, 2026. - The report says the global Lemtrada market is gaining momentum as MS treatment advances and personalized medicine becomes more common. - The report projects continued growth through 2035. - A free sample is available here. - The full report is available here.

The details: - Lemtrada is a prescription drug used to manage autoimmune diseases such as multiple sclerosis. - The drug targets CD52-positive T and B lymphocytes to reduce immune activity that attacks the nervous system. - By depleting these cells, Lemtrada helps reduce inflammation, slow nerve damage, ease symptoms, and slow MS progression. - Past market growth was driven by rising MS incidence, monoclonal antibody innovation, expansion of specialized neurology clinics, approvals for biologic treatments, and better infusion therapy infrastructure. - Future growth is expected to come from demand for high-efficacy MS therapies, tailored immunotherapy strategies, more autoimmune disease research, advanced infusion monitoring technologies, and a greater focus on long-term patient outcomes. - Emerging trends include broader use of immune reconstitution therapies, more targeted autoimmune treatments, continued disease-modification efforts, larger-scale biologic manufacturing, and better safety tracking. - The report points to personalized medicine as a major growth driver because it tailors treatment to a patient’s genetics, environment, and lifestyle. - Lemtrada is positioned as a personalized therapy for relapsing MS, especially for patients with highly active disease who have not responded well to prior treatments. - The Personalized Medicine Coalition said in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - Rising healthcare spending is also supporting market growth by helping governments and insurers subsidize expensive therapies and widen reimbursement access. - The Canadian Institute for Health Information said in November 2023 that Canada’s total health spending was expected to reach $344 billion in 2023, or $8,740 per person, up 2.8% from 2022 growth of 1.5%. - In 2025, North America held the largest share of the global Lemtrada market. - Asia-Pacific is forecast to be the fastest-growing regional market. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables.

Between the lines: - The report frames Lemtrada as part of a broader shift toward more individualized MS care rather than a standalone product story. - The strongest demand signals come from markets that can support specialist treatment, infusion infrastructure, and reimbursement for high-cost biologics. - The regional split suggests mature demand in North America and faster expansion potential in newer or less penetrated markets.

What's next: - The market is expected to keep expanding as MS diagnoses rise and more patients move toward higher-efficacy therapies. - Adoption of advanced infusion monitoring and safety tracking should remain important as clinicians manage complex biologic treatment pathways. - Growth in Asia-Pacific could become a key indicator of how quickly Lemtrada and similar therapies spread beyond established markets. - The Business Research Company says the report’s added forecasting tools and analytics are designed to help track those shifts over time.